Oncotarget

Clinical Research Papers:

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma

Jing-hua Wang, Hua Wang, Yan-jun Wang, Zhong-jun Xia, Hui-qiang Huang, Wen-qi Jiang and Yue Lu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:35412-35422. https://doi.org/10.18632/oncotarget.8643

Metrics: PDF 1104 views  |   HTML 862 views  |   ?  


Abstract

Jing-hua Wang1,2,3,*, Hua Wang1,2,3,*, Yan-jun Wang2,3,4,*, Zhong-jun Xia1,2,3, Hui-qiang Huang2,3,5, Wen-qi Jiang2,3,5 and Yue Lu1,2,3

1 Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

2 State Key Laboratory of Oncology in South China, Guangzhou, China

3 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

4 Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China

5 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

* These authors have contributed equally to this article

Correspondence to:

Yue Lu, email:

Keywords: extranodal NK/T-cell lymphoma, gemcitabine, oxaliplatin, pegaspargase, adverse effects

Received: November 18, 2015 Accepted: March 28, 2016Published: April 07, 2016

Abstract

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Novel L-asparaginase-based treatment regimens, such as GELOX (gemcitabine, oxaliplatin, and L-asparaginase) and P-gemox (gemcitabine, oxaliplatin, and pegaspargase), have shown promising results against stage IE/IIE ENKTL. To define the general applicability of P-gemox, in a retrospective analysis we examined the efficacy and safety of P-gemox in a cohort of 117 patients with newly diagnosed or relapsed/refractory ENKTL. Treatment included 2 to 8 cycles of P-gemox: intravenous gemcitabine (1250 mg/m2) and oxaliplatin (85 mg/m2) and intramuscular pegaspargase (2500 IU/ m2) on day 1 and repeated every 2 weeks, or intravenous gemcitabine (1000 mg/m2) on days 1 and 8 and intravenous oxaliplatin (130 mg/m2) and intramuscular pegaspargase (2500 IU/m2) on day 1 and repeated every 3 weeks. Upon completion of treatment, the overall response rate was 88.8%, and responses were similar for newly diagnosed and relapsed/refractory patients. After a median follow-up of 17 months, the 3-year overall and progression-free survival rates were 72.7% and 57.8%, respectively. Multivariate analysis showed that CR after treatment was the most significant factor affecting survival. P-gemox thus appears to be an effective and well-tolerated treatment for patients with ENKTL.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8643